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Abstract
Hereditary spherocytosis (HS) is a genetic disorder of the red blood cell membrane clinically
characterized by anemia, jaundice and splenomegaly. Evans' syndrome is a clinical syndrome
characterized by autoimmune hemolytic anemia (AIHA) accompanied by immune
thrombocytopenic purpura (ITP). It results from a malfunction of the immune system that produces
multiple autoantibodies targeting at least red blood cells and platelets. HS and Evans' syndrome
have different mechanisms of pathophysiology one another. We reported the quite rare case of an
infant who had these diseases concurrently. Possible explanations of the unexpected complication
are discussed.
Background
Hereditary spherocytosis (HS) is caused by a variety of
molecular defects of erythrocyte membrane proteins.
These proteins are necessary to maintain the normal
shape of erythrocytes. As the spleen normally targets
abnormal shaped red blood cells (RBCs), it also destroys
spherocytes. Autoimmune hemolytic anemia (AIHA) is
the most common autoimmune hemolytic diseases. The
RBC attached antibodies was recognized and grabbed
onto by macrophages in the spleen. These cells will pick
off portions of RBC membrane, that causes spherocytic
change. Spherocytes are not as flexible as normal shaped
RBCs, and will be singled-out for destruction in the retic-
uloendothelial system, that gives rise to extravascular
hemolysis [1]. Immune thrombocytopenic purpura (ITP)
is a condition of having a low platelet count caused by
autoimmune with antibodies against platelets. The coat-
ing of platelets with antibodies renders them susceptible
to opsonization and phagocytosis by splenic macro-
phages [2]. Evans' syndrome refers to a major disorder in
immunoregulation characterized by AIHA accompanied
by ITP [3]. HS and Evans' syndrome have different mech-
anisms of pathophysiology one another. Herein, we
report the first case confirmed Evans' syndrome associated
with HS.
Case presentation
The patient was born at 40 weeks' gestation with 2860 g
by normal spontaneous vaginal delivery after an uncom-
plicated pregnancy. In family history, his mother under-
went splenectomy due to controlling HS when she was 14
years old. At the age of 2 days, he had remarkable jaundice
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without hepatosplenomegaly. Blood chemical values
were as follows: white blood cell (WBC) counts of 17,800/
μl, RBC counts of 5,020 × 103/μl, hemoglobin 18.0 g/dl,
reticulocyte 8.0%, platelet count 305 × 103/μl, total
bilirubin 19.6 mg/dl. His and his mother's blood group
(A, Rh+) were compatible, and his direct anti-globulin test
(DAT) was negative. His erythrocytes showed high
osmotic fragility in erythroresistant test (Table 1). Conse-
quently, we diagnosed him with HS. He immediately
received exchange transfusion for hyperbilirubinemia. He
discharged at 6 days later with no complication. However,
his hemoglobin gradually decreased (less than 7 g/dl)
after leaving our hospital, and erythrocyte transfusion was
needed. Steroid (betamethasone: 0.05 mg/kg) was given
to him for suppressing the splenic function. As a result, his
hemoglobin kept 8 to 9 g/dl without transfusion. During
tapering a dosage of betamethasone, his platelet counts,
but not other blood cell count, had suddenly decreased
(57 × 103/μl) at the age of 6 months. At this time, platelet-
associated immunoglobulin (PAIgG) was high (239.0 ng/
107 cell). Bone marrow examination revealed normal cel-
lularity with increasing of megakaryocytes (305/μl). Incre-
ment of abnormal blasts, hemophagocytes and dysplastic
cells were not found on bone marrow film. IgM-antibod-
ies against cytomegalovirus, human immunodeficiency
virus antibody, anti-nuclear antibody or anti-DNA anti-
body was not detected. He had no clinical feature, which
suggested collagen disease or the coexistence of infectious
diseases (Table 1).
At the age of 8 months he had purpura and gingival bleed-
ing following a cold. Although WBC counts (8,300/μl)
and hemoglobin levels (8.3 g/dl) were unchanged, plate-
let counts progressively decreased (13 × 103/μl) again.
Because a complication of ITP was most suspected, intra-
venous immunoglobulin (IVIG) (1 g/kg) and a dosage of
steroid were administered to him. Unexpectedly, not only
platelet counts (from 13 to 1017 × 103/μl 2 weeks later)
but also hemoglobin levels (from 8.6 to 12.5 g/dl) quickly
increased in association with decrement in reticulocytes
and total bilirubin (from 626 to 229 × 103/μl, from 4.5 to
1.9 mg/dl, respectively) in response to IVIG therapy. At
that time, the percentage of reticulated platelets was 1.3%
(reference value: <2%), and a level of thrombopoietin was
normal (32 pg/mL, reference value: <142 pg/ml). Upshaw
Schulman syndrome was excluded because of only slight
low level of ADAMTS-13 activity (34.7%, reference value:
70-130%) and normal result of von Willebrand factor
multimer analysis [4]. Because the erythrocyte binding
IgG quantitative analysis showed mild elevation in the
patient, we concluded that the infant with HS was accom-
panied by ITP and DAT negative AIHA (Evans' syndrome).
At the age of 10 months after confirming stability of plate-
let counts, tapering betamethasone resulted in gradually
Table 1: Laboratory findings
at 2 days at 6 months at 2 days
WBC 17,200 13,600/μlT S H 7 . 7 2  m U / m l
neut 74 64% FT3 6.1 pg/ml
lym 13 32.5% FT4 4.26 ng/dl
mono 12 1.5% blood group A, Rh (+)
baso 0 0% Direct anti-globulin test negative
eos 0.5 2% Indirect anti-globuin test negative
RBC 5020 × 103 2840 × 103/μl eluate test negative
Ret 8.0 18.4% osmotic fragility in erythroresistant test
Hb 18 8.6 g/dl (after leaving 24 hours)
Ht 53 24.9% osmotic pressure starting hemolysis >0.50% normal saline
Plt 305 × 103 57 × 103/μl osmotic pressure finishing hemolysis 0.42% normal saline
T-Bil 19.6 4.6 mg/dl at 6 months
D-Bil 1.6 mg/dl C3 107 mg/dl
AST 53 32 IU/l C4 24 mg/dl
ALT 9 18 IU/l anti nuclear Ab <40
LDH 797 340 IU/l anti-DNA Ab <2.0 IU/ml
Alp 302 723 IU/l anti-cytomegalovirus IgM 0.58 (EIA)
TP 5.8 6.7 g/dl anti-parvo B-19 IgM 0.32 (EIA)
Alb 3.5 4.8 g/dl PAIgG 239 ng/107 cells
BUN 7 5 mg/dl Direct anti-globulin test (2nd times) negative
Cre 0.64 0.19 mg/dl Indirect anti-globuin test (2nd times) negative
CRP 0.19 0.21 mg/dl Bone marrow examination
nucleated cell count 310 × 103/μl
megakaryocyte 305/μl
abnormal blast not found
phagocyte not found
dysplasia not foundJournal of Hematology & Oncology 2009, 2:40 http://www.jhoonline.org/content/2/1/40
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decreasing hemoglobin levels and platelet counts (hemo-
globin 9 g/dl, platelets 3-5 × 103/μl) as Figure 1 shown.
Methods & results
We examined platelet specific autoantibodies, and eryth-
rocyte binding IgG quantitative analysis based on the
methods as previously described[5,6]. Although a level of
platelet-adhering GPIIb/IIIa antibody slightly increased
(4.1 U/106 cells, reference value: <3.3 U), the number of
GPIIb/IIIa antibody-producing B cells analyzed with
enzyme-linked immunospot (ELISPOT) assay was normal
(0.2/105 peripheral blood mononucleated cells (PBMC),
reference value: <2.0/105 PBMC). With flow cytometric
analysis anti-GPIb, corresponding to CD42b, was not
clearly dyed on the patient platelets (Figure. 2), suggesting
that the existence of autoantibody adhering to GPIb on
the platelets. Taken together, ITP caused by GPIb antibody
but not GPIIb/IIIa was suggested. The erythrocyte binding
IgG quantitative analysis showed mild elevation in the
patient (218 IgG-molecule/RBC (reference value: 33 ±
13)), indicating he had DAT-negative AIHA [7].
Discussion
We reported a case of 6 month-old infant affected by HS,
accompanied by Evans' syndrome. The diagnosis of HS
was made by family history (his mother had already been
diagnoed with HS), a negative DAT, high osmotic fragility
in erythroresistant test and later typical spherocytic mor-
phology.
Platelet surface GPIIb/IIIa and GPIb are the most com-
mon antigenic targets in ITP [8]. No increasing of the
number of B cells producing GPIIb/IIIa antibody in the
patient peripheral blood with ELISPOT assay and the
unbinding of anti-GPIb antibody to the patient's platelets
with flow cytometric analysis suggested that autoantibody
adhering to GPIb on the platelets was responsible for
thrombocytopenia.
The hallmark of AIHA is a positive DAT by which IgG and/
or complement are found on the RBC surface. However,
the incidence of a negative DAT in patients with AIHA has
been reported to be between 2 to 4% [9]. Explanation for
the negative DAT in some patients with AIHA is that the
number of IgG molecules on RBC necessary for acceler-
ated  in vivo destruction is sometimes lower than the
number of that to yield a positive DAT. Because in our
patient anemia improved with a decrement of bilirubin
following IVIG and an erythrocyte binding IgG elevated
moderately, we diagnosed him with AIHA. To our knowl-
edge, there have been two reports that IVIG or corticoster-
oid were effective to HS [10,11]. Compared with those
cases, our patient respond to IVIG and corticosteroid
much better. These findings suggest that anemia in our
patient is partially caused by immunological alteration as
well as thrombocytopenia.
Since the complication of HS with AIHA or ITP has not
been reported previously, it cannot be denied that these
complications occurred coinsidentally. However, it is pos-
Clinical course Figure 1
Clinical course. Evans' syndrome in our patient was devel-
oped when corticosteroid used for suppressing the splenic 
function was tapered. Following a high dose of intravenous 
immunoglobulin and a dosage of steroid, not only platelet 
counts but also hemoglobin levels quickly increased in associ-
ation with decrement in reticulocytes and total bilirubin.
GPIb detection on platelets from normal volunteer and our  patient by flow cytometric analysis Figure 2
GPIb detection on platelets from normal volunteer 
and our patient by flow cytometric analysis. Platelets 
from our patients were negative against FITC-conjugated 
anti-GPIb antibody, suggesting that they were already coated 
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sible to supeculate some explanation for occurring AIHA
or ITP with HS based on the some reason. First, a retro-
spective analysis of blood-bank records showed that out
of 2618 patients who had a positive DAT or indirect anti-
globulin test (IAT), 121 were identified with RBC autoan-
tibodies; 41 of these patients had both allo- and autoanti-
bodies to RBC antigens, whereas the remainder, 80, had
only autoantibodies. At least 34 percent (12/41) of these
patients developed their autoantibodies in temporal asso-
ciation with alloimmunization after recent blood transfu-
sion [12]. Another report showed presence of both an
anti-protein 4.2 antibody and other undefined autoanti-
bodies against RBC associated with heavy transfusions in
protein 4.2-negative HS patient [13]. Although it is
unclear whether transfusion was related to production of
autoreactive antibodies against RBC, it is suspected that
activation of immune sysytem against both external and
internal antigens was elicited by exposing alloprotein
derived from transfused donor's RBC. Second, hypergam-
maglobulinemia may arise when specific helper T cells
recognize B cells that have processed viral antigens irre-
spective of the B cell receptor specificity [14]. This delete-
rious role for nonspecific B cell activation by viral
infection, arguing that it could potentially turn on anti-
self-responses, may contribute to autoantibodies-associ-
ated hemolytic or thrombocytopenic manifestations.
Moreover, Ward et al. has been reported that RBC-autoan-
tigen-specific, interleukin-10-secreting regulatory T cell
clones from a patient with autoimmune hemolytic ane-
mia (AIHA), which had a functional phenotype [15]. Fur-
ther careful observation is required for disclosing that this
complication is not occurred incidentally.
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